Patents by Inventor Claus Bregengaard
Claus Bregengaard has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20040197370Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. The modified Factor VII may be used in conjunction with stents to inhibit coagulation, vascular restenosis, and/or platelet deposition.Type: ApplicationFiled: December 17, 2003Publication date: October 7, 2004Applicant: Novo Nordisk Health Care AGInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Publication number: 20040087498Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: ApplicationFiled: October 1, 2002Publication date: May 6, 2004Applicant: Novo Nordisk Health Care AGInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 6168789Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.Type: GrantFiled: November 10, 1998Date of Patent: January 2, 2001Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 6039944Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: June 5, 1995Date of Patent: March 21, 2000Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5833982Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders, including platelet deposition, vascular thrombosis, ischemic reperfusion, acute closure of a coronary artery, vascular restenosis secondary to balloon angioplasty, endarterectomy, reductive atherectomy, stent placement, laser therapy or rotablation.Type: GrantFiled: June 7, 1996Date of Patent: November 10, 1998Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5817788Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: October 24, 1994Date of Patent: October 6, 1998Assignees: ZymoGenetics, Inc., Novo Nordisk A/SInventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5788965Abstract: The catalytic active site of Factor VII is modified to produce a compound which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma Factors X or IX. Pharmaceutical compositions of the modified Factor VII are used to treat a variety of coagulation-related disorders.Type: GrantFiled: June 7, 1995Date of Patent: August 4, 1998Assignees: Novo Nordisk A/S, ZymoGenetics, Inc.Inventors: Kathleen L. Berkner, Lars Christian Petersen, Charles E. Hart, Ulla Hedner, Claus Bregengaard
-
Patent number: 5621074Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 15, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5618915Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: May 18, 1995Date of Patent: April 8, 1997Assignee: Novo NordiskInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen
-
Patent number: 5591603Abstract: The present invention relates to methods for producing aprotinin and analogs thereof in yeast, synthetic genes encoding such products, expression vectors and transformed yeast cells. The invention further relates to aprotinin analogs, particularly analogs with increased specific inhibitory activity and/or reduced nephrotoxicity compared to native aprotinin, as well as compositions comprising such analogs.Type: GrantFiled: June 23, 1993Date of Patent: January 7, 1997Assignee: Novo Nordisk A/SInventors: Soren E. Bj.o slashed.rn, Kjeld Norris, Viggo Diness, Leif N.o slashed.rskov-Lauritsen, Niels D. Christensen, Claus Bregengaard, Fanny Norris, Lars C. Petersen